Abstract

Background: The metabolic and hormonal axis that connects the dysfunction of adipose tissue with breast cancer has been identified as a very important pathobiological factor, Mostly in communities with high obesity rates like populations of southern Iraq. Adiponectin, which is an adipokine that has been found to inhibit cell growth and enhance insulin sensitivity, is negatively correlated with breast cancer risk However leptin, which is an inflammatory, angiogenic adipokine, helps the tumor grow and become more invasive. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), which is derived from fasting blood glucose and insulin levels, measures systemic insulin resistance, which is a potent breast carcinogenesis activator through the IGF-1 pathway. The current research focuses on the clinical biochemistry profile of serum adiponectin, leptin, and HOMA-IR in breast cancer patients and assesses their potential as independent biomarkers for breast cancer diagnosis and tumor stage stratification. Methods: We carried out a prospective case control study in Maysan Oncology Centre Amarah Iraq, where we collected 80 samples in total. The case group (n = 40) consisted of females with breast cancer that was confirmed by histopathology. These patients were at any stage of breast cancer (AJCC 8th stage) and were sampled before getting any treatment. Control group (n = 40) were healthy women matched individually by age and menopausal status. We performed all biomarker tests on blood samples taken from a fasting state. The amount of serum adiponectin and leptin was determined using a sandwich enzyme-linked immunosorbent assay (ELISA). Fasting insulin was determined by an electrochemiluminescence immunoassay (ECLIA). HOMA-IR was calculated as [fasting glucose (mmol/L) fasting insulin (IU/mL)] / 22.5. Results: Serum adiponectin levels were Quite a bit lower in breast cancer patients (6.34 2.18 vs. 14.82 3.64 g/mL; P < 0.001; Cohen's d = 2.84). In contrast, these patients had much higher leptin (28.74 7.63 vs. 12.46 3.82 ng/mL; P < 0.001; Cohen's d = 2.71) and HOMA-IR (4.26 1.18 vs. 1.94 0.54; P < 0.001; Cohen's d = 2.54) levels. Stage-wise changes of all the three markers showed a consistent worsening trend from AJCC Stages IIV. Besides being independent predictors of breast cancer, they were also the three factors considered by multivariate logistic regression. In ROC analysis, the respective AUC values were 0.948, 0.936, and 0.941. Not only were there very strong inter-marker correlations, significant associations with BMI, lipid profile, and tumour stage were also found. Conclusion: The adiponectin-leptin-HOMA-IR triad is a metabolically hormone-based biomarker panel for breast cancer that is mechanistically consistent, independently validated, and analytically accessible. Their significant stage-dependent changes and strong relationships with metabolic parameters point to adipose tissue dysfunction and insulin resistance as the biochemical promoters of breast cancer in the Maysan female population that can be measured through these biomarker panels.

References

1. Amin, M. B., Edge, S. B., Greene, F. L., Byrd, D. R., Brookland, R. K., Washington, M. K., … Meyer, L. R. (Eds.). (2017). AJCC Cancer Staging Manual (8th ed.). Springer. https://doi.org/10.1007/978-3-319-40618-3
2. Al-Nozha, M. M., Al-Mazrou, Y. Y., Al-Maatouq, M. A., Arafah, M. R., Khalil, M. Z., Khan, N. B., … Al-Harthi, S. S. (2005). Obesity in Saudi Arabia. Saudi Medical Journal, 26(5), 824–829.
3. Alwan, N. A. S. (2016). Breast cancer among Iraqi women: Preliminary findings from a regional comparative breast cancer research project. Journal of Global Oncology, 2(5), 255–258. https://doi.org/10.1200/JGO.2015.003087
4. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., … Matsuzawa, Y. (1999). Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications, 257(1), 79–83. https://doi.org/10.1006/bbrc.1999.0255
5. Barb, D., Williams, C. J., Neuwirth, A. K., & Mantzoros, C. S. (2007). Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. American Journal of Clinical Nutrition, 86(3), S858– S866. https://doi.org/10.1093/ajcn/86.3.858S
6. Bhatt, A. S., Bhatt, D. L., Bhatt, D. K., & Bhatt, A. B. (2012). Adiponectin and cancer: A systematic review. Cancer Epidemiology, Biomarkers & Prevention, 21(8), 1291–1299.
7. Cleary, M. P., & Grossmann, M. E. (2009). Minireview: Obesity and breast cancer: The estrogen connection. Endocrinology, 150(6), 2537–2542. https://doi.org/10.1210/en.2009-0070
8. Dalamaga, M., Diakopoulos, K. N., & Mantzoros, C. S. (2012). The role of adiponectin in cancer: A review of current evidence. Endocrine Reviews, 33(4), 547–594. https://doi.org/10.1210/er.2011-1015
9. Engin, A. (2024). Adiponectin resistance in obesity: Adiponectin leptin/insulin interaction. In Advances in Experimental Medicine and Biology (Vol. 1460, pp. 431–462). https://doi.org/10.1007/978-3-031-63657- 8_15
10. Garofalo, C., & Surmacz, E. (2006). Leptin and cancer. Journal of Cellular Physiology, 207(1), 12–22. https://doi.org/10.1002/jcp.20472
11. Goodwin, P. J., Ennis, M., Fantus, I. G., Pritchard, K. I., Trudeau, M. E., Koo, J., & Hood, N. (2005). Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? Journal of Clinical Oncology, 23(25), 6037–6042. https://doi.org/10.1200/JCO.2005.02.048
12. Hashim, H. T., Ramadhan, M. A., Theban, K. M., Bchara, J., El-Abed-El-Rassoul, A., & Shah, J. (2021). Assessment of breast cancer risk among Iraqi women in 2019. BMC Women’s Health, 21(1), 412. https://doi.org/10.1186/s12905-021-01557-1
13. Kaklamani, V. G., Wisner, J. L., Bhatt, A. S., Bhatt, D. K., & Bhatt, D. L. (2011). Adiponectin and breast cancer risk. Breast Cancer Research, 13(2), R30. https://doi.org/10.1186/bcr2849
14. Kershaw, E. E., & Flier, J. S. (2004). Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology & Metabolism, 89(6), 2548–2556. https://doi.org/10.1210/jc.2004-0395
15. Mantzoros, C. S., Tzonou, A., Signorello, L. B., Stampfer, M., Trichopoulos, D., & Adami, H. O. (1999). Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. British Journal of Cancer, 76(9), 1115–1118. https://doi.org/10.1038/bjc.1997.543
16. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985). Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412–419. https://doi.org/10.1007/BF00280883
17. Pisani, P. (2008). Hyper-insulinaemia and cancer: Meta-analyses of epidemiological studies. Archives of Physiology and Biochemistry, 114(1), 63–70. https://doi.org/10.1080/13813450801954451
18. Pollak, M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer, 8(12), 915– 928. https://doi.org/10.1038/nrc2536
19. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
20. Surmacz, E. (2007). Obesity and breast cancer: The role of leptin. Breast Cancer Research, 9(1), 301. https://doi.org/10.1186/bcr1631
21. World Medical Association. (2013). Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310(20), 2191–2194. https://doi.org/10.1001/jama.2013.281053
22. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994). Positional cloning of the mouse obese gene and its human homologue. Nature, 372(6505), 425–432. https://doi.org/10.1038/372425a0

Download PDF
Back